Hospital Pharmacy Segment to Dominate India Anti-Fungal Drugs Market through FY2027
Supportive government policies and rise
of disposable income is expected to drive the demand for India anti-fungal
drugs market for the forecast period.
According to TechSci Research report, “India
Anti-Fungal Drugs Market By Drug Class (Azoles, Echinocandins, Polyenes,
Allylamines, Others) By Indication (Mucormycosis, Dermatophytosis,
Aspergillosis, Candidiasis, Others (Cryptococcosis, Coccidioidomycosis) By
Infection Type (Superficial Fungal Infection, Systemic Fungal Infection) By
Route of Administration (Oral, Topical, Parenteral, Others) By End-User
(Hospitals, Homecare, Specialty Clinics, Others) By Distribution Channel
(Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By Company, By Region,
Forecast & Opportunities, FY2027”, The India anti-fungal drugs market is
expected to witness steady growth for the next five years. Fungi are defined as
microorganisms which can cause variety of infections such as growth of the
superficial itchy skin upon contact with human body. These kind of infections
takes place due to the presence of low immune systems or exposure to unhygienic
environment containing fungus to the human body. Fungal infections generally occur
on skin, hair and lungs and affects the body adversely. Anti-fungal drugs are
used for treatment of these infections. These anti-fungal drugs can be easily
obtained either through over the counter or through doctor’s prescription.
Surge in number of infectious diseases due to presence of unhygienic conditions
in rural areas is accelerating the demand for anti-fungal drugs in India. Treatment
in healthcare facilities can lead to hospital-acquired diseases such as
nosocomial infections. Also, the other responsible for nosocomial infections
are increasing prevalence of cancer and other diseases which lowers the immune
system of patients.
The COVID-19 outbreak across the world which has
been declared as pandemic by World Health Organization has affected countries
adversely. Leading authorities of India imposed lockdown restrictions and
released a set of precautionary measures to contain the spread of novel
coronavirus. Coronavirus affected patients started suffering from shortness of
breath along with coughing and sneezing. India authorities increased the
capacity of hospitals as a greater number of patients were getting affected
daily and getting admitted into the hospital facilities. Patients suffering
from COVID-19 found to have small amounts of Interferon’s in lungs or blood.
Anti-fungal drugs along with anti-depressant drugs are used widely for
treatment of patients which is expected to positively influence the market
growth.
However, stringent government regulations for
approval of drugs and long-term usage of drugs along with rising side-effects may
hamper the anti-fungal market growth for the forecast period.
Browse XX Figures spread through XX Pages and an in-depth
TOC on “India Anti-Fungal Drugs
Market”.
https://www.techsciresearch.com/report/india-anti-fungal-drugs-market/7491.html
India anti-fungal drugs market is segmented into drug class,
indication, infection type, route of administration, end-user, distribution
channel, regional distribution, and company. Based on indication, market is
further divided into mucormycosis, dermatophytosis, aspergillosis, candidiasis,
and others. The dermatophytosis segment is expected to dominate the market for
the forecast period, FY2023-FY2027. Increase in occurrence of dermatophytosis
across India and presence of unhygienic environmental conditions is fueling the
growth of the anti-fungal drugs market growth. Based on route of administration,
anti-fungal drugs market is majorly classified into oral, topical, parenteral
and others. The topical segment is anticipated to witness significant growth
during the forecast period. Use of topical drugs for treatment of
dermatological fungal infections is a major driver for the anti-fungal drugs
market. Higher concentration of drugs can be applied to affected area and small
number of doses is required for topical drug delivery. Based on distribution channel,
market is fragmented into hospital pharmacy, online pharmacy, and retail
pharmacy. The hospital pharmacy segment is expected to hold lion’s share for
the next five years as large number of patients visit every day for treatment
of various diseases. Increase in awareness regarding health and its benefits is
also expected to boost the anti-fungal drugs market growth.
Pfizer India Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd.,
Sun Pharmaceuticals Industries Ltd., Dr. Reddy’s Laboratories Ltd., Glenmark
Pharmaceuticals Ltd., Lupin Ltd., Zydus Cadila Ltd., Novartis India Ltd.,
Torrent Pharmaceuticals Ltd. are the leading players operating in India anti-fungal
drugs market. Manufacturers are increasingly focusing on research and
development process to fuel higher growth in the market. To meet evolving
customer demand with respect to better efficiency and durability, several anti-fungal
drugs manufacturers are coming up with their technologically advanced
offerings.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7491
Customers can also request for 10% free
customization on this report.
“Manufacturers
are heavily investing to formulate advanced medication techniques for efficient
treatment of anti-fungal diseases. Rise in use of nanotechnology for delivering
medicines with better outcomes such as treatment of nail fungus and launch of
nanostructured drug delivery systems for treatment of vaginal and oral
candidiasis is expected to accelerate the demand for anti-fungal drugs.
Government support for production of anti-fungal on a large scale for treatment
of patients suffering from coronavirus is expected to propel the growth of the
anti-fungal drugs market until FY2027” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based global management consulting firm.
“India Anti-Fungal
Drugs Market By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines,
Others) By Indication (Mucormycosis, Dermatophytosis, Aspergillosis,
Candidiasis, Others (Cryptococcosis, Coccidioidomycosis) By Infection Type
(Superficial Fungal Infection, Systemic Fungal Infection) By Route of
Administration (Oral, Topical, Parenteral, Others) By End-User (Hospitals,
Homecare, Specialty Clinics, Others) By Distribution Channel (Hospital
Pharmacy, Online Pharmacy, Retail Pharmacy) By Company, By Region, Forecast
& Opportunities, FY2027” has evaluated the future growth potential of India anti-fungal
drugs market and provided statistics & information on market size, shares, structure
and future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in the of India anti-fungal
drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/